TY - JOUR
T1 - Pertussis in Asia
T2 - Recent country-specific data and recommendations
AU - participants of the 2019 GPI Thailand Meeting
AU - Jog, Pramod
AU - Memon, Iqbal Ahmad
AU - Thisyakorn, Usa
AU - Hozbor, Daniela
AU - Heininger, Ulrich
AU - von König, Carl Heinz Wirsing
AU - Tan, Tina
N1 - Funding Information:
GPI is funded by an unrestricted educational grant from Sanofi Pasteur. Sanofi Pasteur had no input in the content of this article. Editorial support in the preparation of this manuscript was provided by Phase Five Communications, supported by Sanofi Pasteur.
Publisher Copyright:
© 2021
PY - 2022/2/16
Y1 - 2022/2/16
N2 - The Global Pertussis Initiative (GPI) Roundtable Meeting held in 2019, which preceded the COVID-19 pandemic, focused on the incidence, surveillance, and immunization practices for pertussis in the Asian region. Participants from China, India, Indonesia, Malaysia, Pakistan, Philippines, South Korea, Taiwan, and Thailand presented country-specific information on pertussis prevalence, diagnosis, surveillance, vaccine administration and schedules, maternal and neonatal disease rates, and policies and practice of vaccination during pregnancy. In recent years, many Asian countries have seen an increase in pertussis cases, although underreporting of the disease is a concern. Currently, most Asian countries have only passive surveillance for pertussis in place. There is a need for improved surveillance to determine the disease burden and justify vaccination policies and recommendations, such as essential vaccination, boosters, and vaccination during pregnancy. Better awareness of the disease in adolescents and adults is necessary, and infant and childhood vaccination schedules need to be improved in many countries. Differences between private versus public sector vaccination schedules and between whole-cell and acellular pertussis vaccines should continue to be examined. It can be anticipated that unmet needs in the prevention and management of pertussis will continue as the COVID-19 pandemic evolves and that key recommendations highlighted in this meeting report will be of ongoing importance.
AB - The Global Pertussis Initiative (GPI) Roundtable Meeting held in 2019, which preceded the COVID-19 pandemic, focused on the incidence, surveillance, and immunization practices for pertussis in the Asian region. Participants from China, India, Indonesia, Malaysia, Pakistan, Philippines, South Korea, Taiwan, and Thailand presented country-specific information on pertussis prevalence, diagnosis, surveillance, vaccine administration and schedules, maternal and neonatal disease rates, and policies and practice of vaccination during pregnancy. In recent years, many Asian countries have seen an increase in pertussis cases, although underreporting of the disease is a concern. Currently, most Asian countries have only passive surveillance for pertussis in place. There is a need for improved surveillance to determine the disease burden and justify vaccination policies and recommendations, such as essential vaccination, boosters, and vaccination during pregnancy. Better awareness of the disease in adolescents and adults is necessary, and infant and childhood vaccination schedules need to be improved in many countries. Differences between private versus public sector vaccination schedules and between whole-cell and acellular pertussis vaccines should continue to be examined. It can be anticipated that unmet needs in the prevention and management of pertussis will continue as the COVID-19 pandemic evolves and that key recommendations highlighted in this meeting report will be of ongoing importance.
KW - Asia
KW - Bordetella pertussis
KW - Epidemiology
KW - Pertussis
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85123377318&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123377318&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2021.12.004
DO - 10.1016/j.vaccine.2021.12.004
M3 - Article
C2 - 35074239
AN - SCOPUS:85123377318
SN - 0264-410X
VL - 40
SP - 1170
EP - 1179
JO - Vaccine
JF - Vaccine
IS - 8
ER -